WO1999045126A3 - Activation amelioree de promedicaments - Google Patents

Activation amelioree de promedicaments Download PDF

Info

Publication number
WO1999045126A3
WO1999045126A3 PCT/GB1999/000672 GB9900672W WO9945126A3 WO 1999045126 A3 WO1999045126 A3 WO 1999045126A3 GB 9900672 W GB9900672 W GB 9900672W WO 9945126 A3 WO9945126 A3 WO 9945126A3
Authority
WO
WIPO (PCT)
Prior art keywords
prodrug activation
enhanced
prodrug
enhanced prodrug
activation
Prior art date
Application number
PCT/GB1999/000672
Other languages
English (en)
Other versions
WO1999045126A2 (fr
Inventor
Ian James Stratford
Adam Vorn Patterson
Susan Mary Kingsman
On Kan
Leigh Griffiths
Kyriacos Mitrophanous
Original Assignee
Oxford Biomedica Ltd
Ian James Stratford
Adam Vorn Patterson
Susan Mary Kingsman
On Kan
Leigh Griffiths
Kyriacos Mitrophanous
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9804841.6A external-priority patent/GB9804841D0/en
Priority claimed from GBGB9818103.5A external-priority patent/GB9818103D0/en
Priority claimed from GBGB9902081.0A external-priority patent/GB9902081D0/en
Application filed by Oxford Biomedica Ltd, Ian James Stratford, Adam Vorn Patterson, Susan Mary Kingsman, On Kan, Leigh Griffiths, Kyriacos Mitrophanous filed Critical Oxford Biomedica Ltd
Priority to JP2000534657A priority Critical patent/JP2002505341A/ja
Priority to AU32668/99A priority patent/AU3266899A/en
Publication of WO1999045126A2 publication Critical patent/WO1999045126A2/fr
Publication of WO1999045126A3 publication Critical patent/WO1999045126A3/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/14—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
    • C12Y114/14001—Unspecific monooxygenase (1.14.14.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

L'invention concerne un agent d'activation de promédicaments comprenant: a) un domaine de localisation, et b) un domaine d'activation de promédicaments permettant d'activer un promédicament dans une cellule cible.
PCT/GB1999/000672 1998-03-06 1999-03-05 Activation amelioree de promedicaments WO1999045126A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000534657A JP2002505341A (ja) 1998-03-06 1999-03-05 プロドラッグの活性化の増強
AU32668/99A AU3266899A (en) 1998-03-06 1999-03-05 Enhanced prodrug activation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9804841.6A GB9804841D0 (en) 1998-03-06 1998-03-06 Enhanced pro-drug activation
GB9804841.6 1998-03-06
GBGB9818103.5A GB9818103D0 (en) 1998-08-19 1998-08-19 Enhanced pro-drug activation
GB9818103.5 1998-08-19
GBGB9902081.0A GB9902081D0 (en) 1999-01-29 1999-01-29 Enhanced prodrug activation
GB9902081.0 1999-01-29

Publications (2)

Publication Number Publication Date
WO1999045126A2 WO1999045126A2 (fr) 1999-09-10
WO1999045126A3 true WO1999045126A3 (fr) 2000-02-10

Family

ID=27269233

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB1999/000674 WO1999045127A2 (fr) 1998-03-06 1999-03-05 Activation amelioree de promedicaments
PCT/GB1999/000672 WO1999045126A2 (fr) 1998-03-06 1999-03-05 Activation amelioree de promedicaments

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000674 WO1999045127A2 (fr) 1998-03-06 1999-03-05 Activation amelioree de promedicaments

Country Status (6)

Country Link
EP (1) EP1068338A2 (fr)
JP (1) JP2002505341A (fr)
CN (1) CN1357048A (fr)
AU (2) AU3266899A (fr)
CA (1) CA2322664A1 (fr)
WO (2) WO1999045127A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002530059A (ja) * 1998-11-13 2002-09-17 サイクラセル・リミテッド 輸送ベクター
GB0400443D0 (en) * 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
DE19933492B4 (de) * 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
EP1244796A2 (fr) * 2000-01-07 2002-10-02 ARTEMIS Pharmaceuticals GmbH Transduction de recombinases pour ciblage genetique inductible
EP1272663B1 (fr) * 2000-02-09 2009-12-30 Epidauros Biotechnologie AG Polymorphismes dans le gene humain cyp2b6 et leur utilisation dans des applications diagnostiques et therapeutiques
CN1312283A (zh) * 2000-03-07 2001-09-12 上海博德基因开发有限公司 一种新的多肽——人细胞色素组成蛋白14和编码这种多肽的多核苷酸
EP1504108B1 (fr) 2002-02-01 2013-04-17 Oxford Biomedica (UK) Limited Vecteur lentivirale
WO2007041546A2 (fr) * 2005-10-03 2007-04-12 Genetix Pharmaceuticals, Inc. Methode de depletion selective de cellules hypoxiques
GB0608941D0 (en) * 2006-05-05 2006-06-14 Univ Montfort Methods
WO2009120396A2 (fr) * 2008-01-08 2009-10-01 The University Of California Compositions et procédés permettant de réguler l’expression de l’érythropoïétine, d’améliorer une anémie et de stimuler l’érythropoïèse
JP5488204B2 (ja) * 2010-05-31 2014-05-14 三菱電機株式会社 サイクロン分離装置及びこれを備えた電気掃除機
CN109553688A (zh) * 2012-12-05 2019-04-02 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
JP2017512068A (ja) * 2014-02-17 2017-05-18 ネステク ソシエテ アノニム マイトフュージンの方法及び使用
MX2015006813A (es) * 2015-05-29 2016-11-28 Univ Nac Autónoma De México Nanoparticulas biocataliticas cyp-p22 con actividad citocromo p450 para la activacion de profarmacos.
EP3214092A1 (fr) * 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Promédicaments du modulateur du récepteur de progesterone (sprm) (11.bêta.,17.bêta.)-17-hydroxy-11-[4-(méthylsulphonyle)phenyle]-17-(pentafluoroéthyl)estra-4,9-dièn-3-one
WO2018085586A1 (fr) * 2016-11-02 2018-05-11 David Kiewlich Vecteurs plasmidiques pour l'expression de transgènes d'acide nucléique de grande taille
LT7046B (lt) 2022-04-15 2024-02-12 Vilniaus Universitetas Hidrolazės ir jų panaudojimas

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590530A2 (fr) * 1992-10-02 1994-04-06 BEHRINGWERKE Aktiengesellschaft Protéines de fusion pour l'activation de pro-médicaments
WO1996003515A2 (fr) * 1994-07-27 1996-02-08 Cancer Research Campaign Technology Limited Expression en surface d'une enzyme dans la therapie genique a base de promedicaments
WO1996006166A1 (fr) * 1994-08-20 1996-02-29 Medical Research Council Ameliorations concernant des proteines de liaison permettant de reconnaitre l'adn
WO1997026918A2 (fr) * 1996-01-26 1997-07-31 Cancer Research Campaign Technology Limited Therapie par promedicament a enzyme dirige par ligand

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590530A2 (fr) * 1992-10-02 1994-04-06 BEHRINGWERKE Aktiengesellschaft Protéines de fusion pour l'activation de pro-médicaments
WO1996003515A2 (fr) * 1994-07-27 1996-02-08 Cancer Research Campaign Technology Limited Expression en surface d'une enzyme dans la therapie genique a base de promedicaments
WO1996006166A1 (fr) * 1994-08-20 1996-02-29 Medical Research Council Ameliorations concernant des proteines de liaison permettant de reconnaitre l'adn
WO1997026918A2 (fr) * 1996-01-26 1997-07-31 Cancer Research Campaign Technology Limited Therapie par promedicament a enzyme dirige par ligand

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AKHLYNINA ET AL: "Nuclear Targeting of Chlorin e6 Enhances Its Photosensitizing Activity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 33, 15 August 1997 (1997-08-15), pages 20328 - 20331, XP000198745, ISSN: 0021-9258 *
CHEN ET AL: "Potentiation of Cytochrome P450/Cyclophosphamide-based Cancer Gene Therapy by Coexpression of the P450 Reductase Gene", CANCER RESEARCH, vol. 57, 1 November 1997 (1997-11-01), pages 4830 - 4837, XP002113681 *

Also Published As

Publication number Publication date
AU3266899A (en) 1999-09-20
CN1357048A (zh) 2002-07-03
WO1999045127A2 (fr) 1999-09-10
EP1068338A2 (fr) 2001-01-17
WO1999045126A2 (fr) 1999-09-10
JP2002505341A (ja) 2002-02-19
WO1999045127A3 (fr) 2000-02-24
CA2322664A1 (fr) 1999-09-10
AU3267099A (en) 1999-09-20
AU763020B2 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
WO1999045126A3 (fr) Activation amelioree de promedicaments
AU2002221550A1 (en) Multi-layered body, in particular a multi-layered film and method for increasing the forgery protection of multi-layered body
AU2001261150A1 (en) Methods and systems for compliance program assessment
AU5150500A (en) Trocar for use in deploying an anastomisis device
AU2002227248A1 (en) Low work function material
AU2001244302A1 (en) Assessment methods and systems
MXPA03004758A (es) Pelicula y laminado biodegradable con capacidad de respirar.
AU5419300A (en) Simplified storage barge
AU2002215116A1 (en) Expander
AU3678500A (en) Semi-optimal path finding in a wholly unknown environment
AU2000262575A1 (en) Method for localising direction and localisation arrangement
EP1151667A3 (fr) Agent d'activation de plantes
AU2001262216A1 (en) Apoptotic agents
AU2001264504A1 (en) Random identity management in scatternets
AU2002215741A1 (en) Semen storage
AU2001253104A1 (en) Methods for altering t cell and macrophage activation
AU6737800A (en) Polymer for chemically amplified resist and a resist composition using the same
AU2002234081A1 (en) Rapid development in a distributed application environment
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2001261374A1 (en) Message authentication using message gates in a distributed computing environment
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AU2001269257A1 (en) Target face
AU2002241514A1 (en) Systems and methods for communicating in a business environment
AU2611899A (en) An electricity distribution board having a distribution terminal block, and a distribution terminal block for use in the electricity distribution board
WO2000078274A3 (fr) Composition de colorant capillaire

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99805649.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase